 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...197198199200201202203204205206207...208209» |
- | NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Trial completion: Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=48, Completed, Sponsor: Novaliq GmbH
Recruiting --> Completed
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date: Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - Jun 29, 2017
P1, N=70, Recruiting, Sponsor: Hengrui Therapeutics, Inc.
Recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2019
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open, PD(L)-1 Biomarker, IO biomarker: A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients (clinicaltrials.gov) - Jun 27, 2017
P1, N=30, Recruiting, Sponsor: Atridia Pty Ltd.
Trial primary completion date: Dec 2017 --> Dec 2019 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial: Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC (clinicaltrials.gov) - Jun 27, 2017
P1/2, N=48, Recruiting, Sponsor: West China Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer (clinicaltrials.gov) - Jun 26, 2017
P2, N=40, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 26, 2017
P2, N=21, Recruiting, Sponsor: Hangzhou Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 20, 2017
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer (clinicaltrials.gov) - Jun 20, 2017
P2, N=50, Recruiting, Sponsor: Chang-Ming Huang, Prof.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 20, 2017
P2, N=120, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Trial primary completion date: Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma (clinicaltrials.gov) - Jun 16, 2017
P1/2, N=40, Recruiting, Sponsor: The First People's Hospital of Lianyungang
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Jul 2018
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients (clinicaltrials.gov) - Jun 16, 2017
P2, N=20, Not yet recruiting, Sponsor: Xinqiao Hospital of Chongqing
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects (clinicaltrials.gov) - Jun 15, 2017
P1, N=20, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- ||||| ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P2 trial: Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (clinicaltrials.gov) - Jun 14, 2017
P2, N=200, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer (clinicaltrials.gov) - Jun 14, 2017
P2, N=21, Recruiting, Sponsor: Hangzhou Cancer Hospital
- ||| SHR7390 / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / Elevar Therapeutics, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 8, 2017
P1, N=60, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial primary completion date: A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) - Jun 8, 2017
P1, N=42, Recruiting, Sponsor: Atridia Pty Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Jun 2018
- | AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jun 7, 2017
P2, N=24, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: NRT-01: Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Jun 7, 2017
P1/2, N=40, Recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Trial primary completion date: May 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma?FACT? (clinicaltrials.gov) - Jun 1, 2017
P3, N=543, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Nov 2017
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib Treatment for Advanced Esophagus Cancer (clinicaltrials.gov) - May 31, 2017
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: NRT-01: Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - May 31, 2017
P1/2, N=40, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- | Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Trial primary completion date, PD(L)-1 Biomarker: Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - May 31, 2017
P1/2, N=39, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Nov 2017 Trial primary completion date: Sep 2017 --> Mar 2018
- ||| SHR7390 / Jiangsu Hengrui Pharma
Enrollment open: Phase I Study of SHR7390 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 30, 2017
P1, N=60, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Sep 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma (clinicaltrials.gov) - May 30, 2017
P2, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- |||||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, PD(L)-1 Biomarker, IO biomarker: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - May 30, 2017
P3, N=412, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: SHR-1210-III-301-ESC: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer (clinicaltrials.gov) - May 30, 2017
P3, N=438, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov) - May 24, 2017
P2, N=128, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. (clinicaltrials.gov) - May 23, 2017
P2, N=40, Recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Mesylate Apatinib for Stage ? STS After Failure of Chemotherapy (clinicaltrials.gov) - May 22, 2017
P2, N=80, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P1 trial: Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient (clinicaltrials.gov) - May 18, 2017
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P1 trial: Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment (clinicaltrials.gov) - May 18, 2017
P1, N=32, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy: Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 18, 2017
P3, N=450, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (clinicaltrials.gov) - May 16, 2017
P2, N=36, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer (clinicaltrials.gov) - May 15, 2017
P2, N=48, Not yet recruiting, Sponsor: Zhou Fuxiang
- ||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma (clinicaltrials.gov) - May 15, 2017
P2, N=60, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. (Pubmed Central) - May 11, 2017
Taken together, the simultaneous administration of apatinib and cisplatin improves the therapeutic efficacy over standalone treatments, which also led to improved efficacy over sequential administration regimens. VEGFR-2 is an important predictive marker for efficacy of apatinib treatment of NPC.
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib_GC: Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer. (clinicaltrials.gov) - May 9, 2017
P2, N=110, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers (clinicaltrials.gov) - May 9, 2017
P2, N=39, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Phase classification, Metastases: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) - May 6, 2017
P2, N=37, Recruiting, Sponsor: Peking University People's Hospital
VEGFR-2 is an important predictive marker for efficacy of apatinib treatment of NPC. Available --> Recruiting | Phase classification: PN/A --> P2
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy (clinicaltrials.gov) - May 1, 2017
P2, N=36, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial, PD(L)-1 Biomarker, IO biomarker: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - Apr 30, 2017
P3, N=412, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial, PD(L)-1 Biomarker, IO biomarker: A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients (clinicaltrials.gov) - Apr 27, 2017
P1, N=30, Not yet recruiting, Sponsor: Atridia Pty Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2017
P2, N=40, Not yet recruiting, Sponsor: Yanqiao Zhang
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout (clinicaltrials.gov) - Apr 27, 2017
P1, N=15, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: EASE: An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 26, 2017
P2, N=52, Recruiting, Sponsor: Changzhou Cancer Hospital of Soochow University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Monotherapy: The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer (clinicaltrials.gov) - Apr 26, 2017
P2, N=52, Recruiting, Sponsor: Junling Li
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 26, 2017
P2, N=25, Recruiting, Sponsor: Guilin Medical University, China
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial primary completion date: A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 25, 2017
P1, N=30, Recruiting, Sponsor: Atridia Pty Ltd.
Available --> Recruiting | Phase classification: PN/A --> P2 Trial primary completion date: Jun 2018 --> Jan 2018
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites (clinicaltrials.gov) - Apr 25, 2017
P2, N=120, Recruiting, Sponsor: First Affiliated Hospital Bengbu Medical College
Trial primary completion date: Jun 2018 --> Jan 2018 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases (clinicaltrials.gov) - Apr 25, 2017
P2, N=40, Not yet recruiting, Sponsor: Affiliated Hospital of Hebei University